macology: nes and ART nia Poteat, MMSc, MPH, PA-C hase Brexton Health Services pkins School of Public Health

Similar documents
HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

HIV 1. A reference guide for prescription HIV-1 medications

Covered California s 2016 Formularies

Drug Treatment Program Update

Comprehensive Case Management Reassessment

Systematic literature search: PICO questions

Helpful HIV Medication Tables for Pharmacists

862060_Rec Drug Guide.qxd 2/5/14 1:06 PM Page 1. Recreational Drugs and HIV Antiretrovirals. A Guide to Interactions for Clinicians

B.C. HIV/AIDS Drug Treatment Program

Marketplace Health Plans Template Assessment Tool October 2014

Generic antiretrovirals in Europe: a blessing or a curse?

Chemotherapy regimen: Dose adjusted EPOCH

Opioid Pain and Addiction Management Medications Drug. Interactions with HIV Antiretrovirals. A Drug Interaction Guide for Clinicians.

GENERAL INSTRUCTIONS FOR COMPLETING THE HIV TEST FORM

CO-PAY PROGRAMS FOR HIV and Hepatitis

London Therapeutic Tender Implementation: Guidance for Clinical Use. 4 th June 2014 FINAL

STATE HEALTH REFORM IMPACT MODELING PROJECT. Alabama

Treatment Information Service HIV 0440 HIV/AIDS. HIV and Its Treatment What You Should Know. 2nd edition

North Carolina Marketplace Plans with More Affordable Drug Cost Sharing for People with HIV

South CarolinaJanuary 2013

Antiretroviral Patient Medication Information Sheets Table of Contents

Presented by: Canadian Working Group on HIV and Rehabilitation

HIV and the Central Nervous System: neurocognitive aspects VIH y Sistema Nervioso Central: aspectos neurocognitivos

HIV Update: Epidemiology and Pathophysiology

1/26/2015. Epidemiology of the Epidemic: World. Epidemiology of the Epidemic: United States. HIV Update: Epidemiology and Pathophysiology

State Health Reform Impact Modeling Project Florida

ACA Insurance Enrollment for People living with HIV in North Carolina

The treatment of HIV is currently focused on drug

STATE HEALTH REFORM IMPACT MODELING PROJECT. North Carolina

District of Columbia

Maryland. State Health Reform Impact Modeling Project

State Health Reform Impact Modeling Project Tennessee

HIV/AIDS 2014 REPORT MEDICINES IN DEVELOPMENT. Contents. Medicines and Vaccines in Development for HIV Infection

Understanding Pharmacokinetic Variability and Managing Drug Interactions

Direct antiviral therapy of hcv and relevant drug drug interactions for ivdu

New Jersey. State Health Reform Impact Modeling Project

STATE HEALTH REFORM IMPACT MODELING PROJECT. Georgia

Patient Information Leaflet Drug interaction with ED drug treatments

Chapter 3 South African guidelines and introduction to clinical cases

CHAPTER 2B HIV DRUG-DRUG INTERACTIONS I. INTRODUCTION GENERAL RECOMMENDATIONS:

Contents What are side effects? Why do I need to know about side effects of HIV medications?

Bristol-Myers Squibb and Gilead Sciences, LLC 50

The Antiretroviral. Pregnancy Registry. Interim Report VOL. 28, NO. 1 1 JANUARY 1989 THROUGH 31 JANUARY Interim Report. (Issued: June 2016)

Herta Crauwels, et al.: Rilpivirine Drug-Drug Interactions

Living With HIV A guide to your long-term health

HIV ONCOLOGY HANDBOOK. Antiretroviral Interactions with Chemotherapy Regimens. Alison Wong, B.pharm., M.Sc. Alice Tseng, Pharm.D.

It s In The Cards: Pharmaceutical Co-pay and Patient Assistance Programs. Jeff Berry Editor, Positively Aware

FARMACI, INNOVAZIONE e INFEZIONE DA HIV / AIDS

Drug/Drug and Drug/Food Interactions with Target-Specific Oral Anticoagulants

HCV/HIVCo-infection A case study by. Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre

Drug-Drug Interactions with Antiretroviral Therapy. Case-Based Discussions

POST-EXPOSURE PROPHYLAXIS IN THE HEALTH CARE SETTING

Drug Interactions in HIV/HCV coinfection

HIV/Hepatitis C co-infection. Update on treatment Eoin Feeney

Access and coverage of antiretroviral drugs through Canada s provincial and territorial drug programs

From Drug Holidays to 100% Adherence- The Role of the Pharmacist in HIV Drug Therapy - FL APPROVED -

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS. Carl LeBuhn, MD

Antiretroviral therapy for HIV infection in infants and children: Towards universal access

The Role of the Primary Care Clinician in HIV Care

CDC occupation Codes used to code ( map ) facility locations

Pharmacoprevention. HIV-drugs for prevention. Instituut Tropische Geneeskunde, Antwerpen

HIV Drug Therapy. Handbook of VOLUME ONE. Treatment and Pharmacologic Information

AfricanEyeVOICE. Meet the world s strongest HIV Positive Campaigner: Milly Katana. plus Treatment News Treatment Q&A History of HIV and much more...

Education grant to fund the project

AIDS ACCESS FOUNDATION/ MSF AIDS can be Treated: A handbook of Antiretroviral medicines. AIDS Can Be Treated. A Hand Book of Antiretroviral medicines

Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH

Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C. Daclatasvir (Daklinza, DCV, BMS )

Harvoni (Ledipasvir/Sofosbuvir) Treatment Agreement

This lecture offers theoretical and practical information about drug interactions in antiretroviral therapy.

Foreword... 2 Acknowledgements Background of AIDSRelief ART Supply Chain Management... 8

Postexposure Prophylaxis (PEP)

Meeting Report 15 th PK Workshop, Washington, 2014 Produced by

ARV treatment Update Avondseminarie 18 december 2012 Eric Florence ITG, Antwerpen

Drug Interactions in Managing HIV/HCV Co-Infection Presenter: Christopher Keeys, Pharm.D., BCPS 28 October 2015

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Bioequivalence Study Design Considerations. Dr. John Gordon

Management of HIV and TB Co-infection in South Africa

How To Treat Anaphrodic Acid With Atripla

Managing HIV Patients with Cardiac Disease: How to Avoid Going Into Heart Failure (the clinician, not the patient)

Daclatasvir (Daklinza)

EACS Dominique Braun Universitätsspital Zürich

Patent Expiry Impact Predictor

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006)

LIQUID DRUG FORMULATIONS. Formulation Status Cost Comments. facilitated access

Treatment 2.0 as a catalyst for Tasp through Drug / Treatment Optimization

HELPFUL TIPS WHEN FACING CHRONIC HEPATITIS C

Pharmacodynamics and Drug-Drug Interactions in HCV/HIV Co-Infected Persons on Treatment with DAAs

VILMA M. VEGA, M.D. CURRICULUM VITAE

The Novel Oral Anticoagulants

Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications

Adherence to oral cancer therapies

Regulatory Approach in Germany and in the EU to Fixed Dose Combination Medicinal Products Using HIV/AIDS Treatment as an Example

Interactions Between Antiretrovirals and Antiplatelet Agents and Novel Oral Anticoagulants

Social and Economic costs of HIV and AIDS. Current issues. Sarah Ann Adomakoh. Costs, cost-effectiveness & Sustainability

Clinical Commissioning Policy: Stribild for the treatment of HIV-1 infection in adults

Antiretroviral Treatment

Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation. M Dinaker. Fig.1: Effect of CART on CD4 and viral load

Drug drug interaction of new HCV drugs

Managing Drug Interactions in Hepatitis C: A Case-Based Approach

The question and answer session is not available after the live webinar.

Transcription:

Pharm macology: Hormon nes and ART Ton nia Poteat, MMSc, MPH, PA-C Ch hase Brexton Health Services Johns Hop pkins School of Public Health

HIV-R Related Drug Inte eractions Image: thebody.com

Drug Metabolism Metabolism of some drug gs occurs along cytochrome P-450 iso-enzyme pathway (mos st common = 3A4 and 2D6) Two or more drugs using this pathway will interact Affecting potency, side effects, & effectiveness Drug concentrations may go up or down Difficult to predict the effects of multiple drug interactions Enzyme Inducers Increase metabolism Decrease amount of dr rug in bloodstream unless it s a pro-dru ug Enzyme Inhibitors Decrease metabolism Increase the amount of drug in bloodstream Unless it s a pro-dr rug Lynch AAFP 2007

Cytochrome (CYP P) P450 metabolism Common inducers Smoking St. John s Wort All Protease Inhibito ors NNRTI s Common inhibitors Grapefruit Statins Azoles (anti-fungals) Mixed inducer/inhibitor r Efavirenz www.aidsetc.org

Chanelle 28 year old trans woman with HIV +THC (no cigarette es), non-drinker Taking Delestroge en on the street whenever she can get it. Uns sure of dose. CD4 count 250 & VL 173,000 ALT 60, Cr 1.0, Hep C+, Hep A&B immune Rest of CBC and CMP are unremarkable Feels ready to sta art ARVs What are her optio ons? What else might you want to do?

Available Antiretrov viral Agents: June 2011 NRTIs Abacavir (Ziagen) Didanosine (Videx) Emtricitabine (Emtriva) Lamivudine (Epivir) Stavudine (Zerit) Tenofovir (Viread) Zidovudine (Retrovir) 3TC/ABC (Epzicom) 3TC/ABC/ZDV (Trizivir) 3TC/ZDV (Combivir) FTC/TDF (Truvada) NNRTIs Delavirdine (Rescriptor) Efavirenz (Sustiva) Nevirapine (Viramune) Etravirine (Intelence) Rilpivirine (Edurant) Multiple Class Atripla (EFV/FTC/TDF) PIs Atazanavir (Reyataz) Darunavir (Prezista) Fosamprenavir (Lexiva) Indinavir (Crixivan) Lopinavir/ritonavir (Kaletra) Nelfinavir (Viracept) Ritonavir (Norvir) Saquinavir (Invirase) Tipranavir (Aptivus) Fusion Inhibitors (FIs) Enfuvirtide (Fuzeon) Integrase Inhibitor Raltegravir (Isentress) CCR5 Inhibitor Maraviroc (Selzentry)

Chanelle - 3 mon nths later Switched to oral estradiol 4mg daily plus 100mg twice daily of spironolactone. Started on TDF/FT TC + ATV + RTV Denies any side ef ffects CD4 increased to 400, UDVL ALT increased to 100, Cr 1.45 Complains of ho ot flashes What drug interac ctions may be at play? What might you want to do?

PI s and Hormona al Contraceptives DHHS Guidelines January 10, 2011 Ritonavir-boosted Protease Inhibitors Atazanavir/r EE norgestimate Use OCP >35mcg EE Darunavir/r EE norethindrone Use alternative method Fosamprenavir/r EE norethindrone Use alternative method Lopinavir/r EE norethindrone Use alternative method Saquinavir/r EE Use alternative method Tipranavir/r EE no norethindrone Use alternative method Protease Inhibitors without Ritonavir Atazanavir Fosamprenavir EE norethindrone APV EE and norethindrone EE APV by 20% Use OCP >35mcg EE Use alternative method

NNRTI s and Horm monal Contraceptives Efavirenz Etravirine EE Levenorgestrel Norelgestromin EE No Norethindrone Use alternative methods. Norelgestromin & levonorgestrel are active metabolites of norgestimate. No dose adjustment necessary Nevirapine EE Norethindrone No DMPA Use alternative methods No dose adjustment necessary DHHS Guidelines January 10, 2011

Other ARVs & Ho ormonal Contraception CCR5 Antagonist Maraviroc No EE or levonorgestrel Safe to use together Integrase Inhibitor Raltegravir No clinically sig gnificant effect Safe to use together DHHS Guidelines January 10, 2011

Chanelle - 6 mon nths later Pt was switched back to Delestrogen at 40mg IM every oth her week and continues spironalactone at previous doses. She returns with resolution of symptoms Stable on ARVs an nd hormone therapy Wants to address her Hepatitis C CD4 count 500, UDVL, Hep C genotype 1 HCV RNA 750,0 000; ALT 80; Cr 1.2 No known contr raindications to treatment What drug interac ctions concern you?

Drug Interactionn Estradiol levels are DECREASED by: Rifampin Dexamethasone Naphthoflavone Smoking cigarette es Carbamazepine Phenytoin Phenobarbital Telaprevir www.hivwebstudy.org

Chanelle 4 week ks later She has started Pe eg-ifn, RBV, and Telaprevir* She complains of depressive symptoms; denies suicidal ide eation She doesn t want to take pharmaceuticals and wants to try somet thing natural like St. John s Wort. What do you recom mmend? *Telaprevir has not been FDA-approved for use in HIV-HCV co-infected patients. This is an off-label use of this medication.

Cytochrome (CYP P) P450 metabolism Common inducers Smoking St. John s Wort All Protease Inhibito ors NNRTI s Common inhibitors Grapefruit Statins Azoles (anti-fungals) Mixed inducer/inhibitor r Efavirenz www.aidsetc.org

Drug Interactionn Estradiol levels are INCREASED by: Isoniazid Fluvoxamine Fluoxetine Sertraline Paroxetine Diltiazem Verapamil Cimetidine Astemizole Itraconazole Ketoconazole Fluconazole Miconazole Clarythromycin Erythromycin Grapefruit www.hivwebstudy.org

Chanelle 8 week ks later She was started on ci italopram and depressive symptoms have impro oved Her labs are stable an nd she continues on the following medications s: Peg-IFN, RBV, and Telaprevir Tenofovir/Emtricit tabine, Atazanavir, Norvir Delestrogen, Spiro onolactone While she doesn t like the pill burden, she is tolerating meds well and happy to be able to get her all her care in the sam me place.

Summary: Estrog gens & Antiretrovirals DHHS evidence based on oral contraceptives Oral contraceptive es use ethinyl estradiol at contraceptive dose es Hormones for trans sgender patients usually are 17-β estradiol or conjug gated equine estrogen (CEE) Most PI interactions decrease estrogen levels If estrogen is conti inued and antiretrovirals are stopped, this may lead to dangerously high estrogen levels with associa ated risk of adverse effects Non-nucleosides (NN NRTI) Nevirapine decreas ses estrogen levels Efavirenz may incr rease or decrease estrogen levels

Take Home Mes ssage Amprenavir and Fosamprenavir are the only antiretroviral ls that should not be co- administered with estrogen due to risk of virologic failure. Several HIV medic cations change the levels of estrogens, ther refore estrogen dose adjustment may be necessary Gender confirming hormone therapy is not contraindicated with antiretroviral therapy.

Web Resources fo or Drug Interactions http://www.healthline.co om/druginteractions http://reference.medsca ape.com/drug- interactionchecker http://www.drugs.com/d drug_interactions.html

Expert Advice at Yo our Fingertips HIV/AIDS Clinic cal Consultation 1-800-933-3413 3 Mon-Fri 8am to 8pm EST www.ucsf.edu/ /hivcntr